The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis
Authors:
- Reza Amani-BeniRAReza Amani-Beni
- Bahar DaroueiBDBahar Darouei
- Davood ShafieDSDavood Shafie
- Mohammadreza MortahebMMMohammadreza Mortaheb
- Mohammadreza MalakoutikhahMMMohammadreza Malakoutikhah
- Amirhossein EbrahimiAEAmirhossein Ebrahimi
- Sara Heidari-HasanabadiSHSara Heidari-Hasanabadi
- Mehrdad Rabiee RadMRMehrdad Rabiee Rad
- Ghazal Ghasempour DabaghiGDGhazal Ghasempour Dabaghi
- Sadegh Mazaheri-TehraniSMSadegh Mazaheri-Tehrani
- Ehsan Amini-SalehiEAEhsan Amini-Salehi
- Amir Parsa AbhariAAAmir Parsa Abhari
Open Access
- 3 April 2025
- journal article
- review article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 25 (1) , 1-17
Abstract
Managing electrolyte abnormalities, particularly sodium and potassium, in patients with heart failure (HF) remains a concern. A novel anti-diabetic drug, sodium-glucose co-transporter-2 (SGLT2) inhibitors, has become suitable for HF patients, improving cardiovascular outcomes. Therefore, we aimed to conduct a meta-analysis to evaluate the effect of SGLT2 inhibitors on serum sodium and potassium. We systematically searched five databases, identifying randomized clinical trials (RCTs) reporting changes in serum sodium and potassium levels with SGLT2 inhibitors compared to comparator groups. Outcomes were presented as weighted mean differences (WMD) and standardized MD (SMD) with 95% confidence intervals (CI). Subgroup and sensitivity analyses were also conducted. 13 studies were included, with 13 studies with 10,617 participants reporting on serum sodium and nine studies with 9877 participants on serum potassium. In acute HF, SGLT2 inhibitors did not significantly affect serum sodium (WMD: 1.21 mmol/L; 95% CI: − 0.79, 3.21) or potassium levels (WMD: 0.11 mEq/L; 95% CI: − 0.20, 0.42). Subgroup analyses suggested possible variations by follow-up duration (< 7 days vs. ≥ 30 days) and drug type, but findings remained non-significant. Sensitivity analysis using the leave-one-out method and risk of bias assessment results showed no considerable changes in the statistical significance of the pooled results. Similarly, in chronic HF, no significant differences were observed for serum sodium (WMD: 0.23 mmol/L; 95% CI: − 0.45, 0.91) or potassium (WMD: 0.07 mEq/L; 95% CI: − 0.29, 0.44). Sensitivity and subgroup analyses based on duration, drug type, diabetes status, renal function, or systolic blood pressure did not reveal clinically meaningful differences across all analyses. For all analyses, Egger’s test was non-significant, indicating no strong evidence of small‐study effects. Moreover, the trim-and-fill method combined with the funnel plot did not identify any missing studies, and the recalculated effect size remained unchanged. SGLT2 inhibitors did not significantly alter serum sodium or potassium levels in acute or chronic HF, suggesting that these drugs can be safe regarding electrolyte disturbances. Additional RCTs are warranted to enhance the robustness of evidence regarding the mechanisms and effects of SGLT2 inhibitors on serum electrolyte levels, considering variations across different types of SGLT2 inhibitors.Keywords
This publication has 70 references indexed in Scilit:
- Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart FailureESC Heart Failure, 2025
- Effects of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function in Patients with Chronic Heart FailureESC Heart Failure, 2021
- Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failureEuropean Journal of Heart Failure, 2021
- Effect of dapagliflozin on anaemia in DAPA‐HFEuropean Journal of Heart Failure, 2021
- Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trialEuropean Journal of Heart Failure, 2021
- Risk of Bias 2 in Cochrane Reviews: a phased approach for the introduction of new methodologyCochrane Database of Systematic Reviews, 2020
- Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial (CANDLE)ESC Heart Failure, 2020
- Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data from 9222 Chronic Heart Failure Patients of the ESC-HFA-EORP Heart Failure Long-Term RegistryEuropean Journal of Heart Failure, 2020
- Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)European Journal of Heart Failure, 2020
- The Use of Diuretics in Heart Failure with Congestion — A Position Statement from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2019